Scarica l'app Stockscreener
7.57
2.44%
0.18
Dopo l'orario di chiusura:
7.63
0.06
+0.79%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché BCRX Giù?
Forum
Previsione
Precedente Chiudi:
$7.39
Aprire:
$7.25
Volume 24 ore:
4.79M
Relative Volume:
2.42
Capitalizzazione di mercato:
$1.57B
Reddito:
$331.41M
Utile/perdita netta:
$-226.54M
Rapporto P/E:
-6.056
EPS:
-1.25
Flusso di cassa netto:
$-97.31M
1 W Prestazione:
+0.53%
1M Prestazione:
+3.70%
6M Prestazione:
+23.09%
1 anno Prestazione:
+34.22%
Intervallo 1D:
$7.25
$7.60
Intervallo di 1 settimana:
$7.1501
$7.62
Portata 52W:
$4.03
$8.88
Biocryst Pharmaceuticals Inc Stock (BCRX) Company Profile
Nome
Biocryst Pharmaceuticals Inc
Settore
Industria
Telefono
919-859-1302
Indirizzo
4505 EMPEROR BOULEVARD, DURHAM, NC
Confronta BCRX con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
BCRX
Biocryst Pharmaceuticals Inc
|
7.57 | 1.57B | 331.41M | -226.54M | -97.31M | -1.18 |
|
VRTX
Vertex Pharmaceuticals Inc
|
397.27 | 102.31B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
701.85 | 77.13B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
623.82 | 37.30B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
245.44 | 31.66B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
113.08 | 27.11B | 3.30B | -501.07M | 1.03B | -2.1146 |
Biocryst Pharmaceuticals Inc Stock (BCRX) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2023-11-20 | Ripresa | JP Morgan | Overweight |
| 2023-09-18 | Aggiornamento | RBC Capital Mkts | Sector Perform → Outperform |
| 2023-08-04 | Aggiornamento | Jefferies | Hold → Buy |
| 2023-07-13 | Aggiornamento | BofA Securities | Neutral → Buy |
| 2023-02-22 | Aggiornamento | Needham | Hold → Buy |
| 2022-11-02 | Aggiornamento | Evercore ISI | In-line → Outperform |
| 2022-08-05 | Downgrade | Evercore ISI | Outperform → In-line |
| 2022-08-05 | Downgrade | Oppenheimer | Outperform → Perform |
| 2022-04-18 | Downgrade | Barclays | Overweight → Equal Weight |
| 2022-04-11 | Downgrade | BofA Securities | Buy → Neutral |
| 2021-12-10 | Iniziato | Oppenheimer | Outperform |
| 2021-08-06 | Downgrade | Jefferies | Buy → Hold |
| 2021-08-03 | Iniziato | Cantor Fitzgerald | Overweight |
| 2021-03-01 | Iniziato | Cowen | Outperform |
| 2020-09-29 | Ripresa | JP Morgan | Overweight |
| 2020-06-17 | Iniziato | BTIG Research | Neutral |
| 2020-05-05 | Aggiornamento | Barclays | Equal Weight → Overweight |
| 2019-11-15 | Aggiornamento | BofA/Merrill | Neutral → Buy |
| 2019-05-24 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| 2018-11-16 | Ripresa | Piper Jaffray | Overweight |
| 2018-08-08 | Ripresa | JP Morgan | Overweight |
| 2018-07-17 | Aggiornamento | BofA/Merrill | Underperform → Neutral |
| 2018-06-22 | Iniziato | Seaport Global Securities | Neutral |
| 2018-01-02 | Aggiornamento | RBC Capital Mkts | Sector Perform → Outperform |
| 2017-12-20 | Iniziato | Barclays | Equal Weight |
| 2017-09-15 | Iniziato | RBC Capital Mkts | Sector Perform |
| 2017-09-06 | Aggiornamento | JP Morgan | Neutral → Overweight |
| 2017-09-06 | Aggiornamento | Jefferies | Hold → Buy |
| 2017-02-16 | Iniziato | Ladenburg Thalmann | Buy |
| 2016-08-12 | Aggiornamento | Piper Jaffray | Neutral → Overweight |
| 2016-08-04 | Downgrade | JMP Securities | Mkt Outperform → Mkt Perform |
| 2016-02-09 | Reiterato | FBR Capital | Outperform |
| 2016-02-09 | Downgrade | JP Morgan | Overweight → Neutral |
| 2016-02-09 | Downgrade | Needham | Buy → Hold |
Mostra tutto
Biocryst Pharmaceuticals Inc Borsa (BCRX) Ultime notizie
107,820 Shares in BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) Acquired by Wellington Management Group LLP - MarketBeat
Trading (BCRX) With Integrated Risk Controls - Stock Traders Daily
XTX Topco Ltd Cuts Position in BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) - MarketBeat
KalVista stock wins new Buy at BofA (KALV:NASDAQ) - Seeking Alpha
State Street Corp Trims Position in BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) - MarketBeat
BioCryst Pharmaceuticals (NASDAQ:BCRX) Shares Gap DownHere's Why - MarketBeat
Biocryst Pharmaceuticals director Nancy Hutson sells $52,780 in stock - Investing.com
Verition Fund Management LLC Sells 102,839 Shares of BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) - MarketBeat
BioCryst Pharmaceuticals: Seasoned Blockbuster Makes It A Buy - Seeking Alpha
Charles Schwab Investment Management Inc. Boosts Holdings in BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) - MarketBeat
Two Sigma Advisers LP Acquires 261,500 Shares of BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) - MarketBeat
The Manufacturers Life Insurance Company Has $2.27 Million Stock Position in BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) - MarketBeat
Jacobs Levy Equity Management Inc. Trims Stock Holdings in BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) - MarketBeat
High Growth Tech Stocks To Watch In December 2024 - Yahoo Finance
BNP Paribas Financial Markets Has $3.78 Million Stake in BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) - MarketBeat
BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire
BioCryst Pharmaceuticals Awards Stock Options, RSUs to New Employees in Inducement Package - StockTitan
BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) Receives $15.60 Consensus Target Price from Analysts - MarketBeat
Cinctive Capital Management LP Takes Position in BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) - MarketBeat
BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) is Caligan Partners LP's 7th Largest Position - MarketBeat
Fisher Asset Management LLC Increases Stock Position in BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) - MarketBeat
(BCRX) On The My Stocks Page - Stock Traders Daily
Market Sentiment Around Loss-Making BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) - Simply Wall St
Algert Global LLC Grows Position in BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) - MarketBeat
BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) Is Expected To Breakeven In The Near Future - Yahoo Finance
Connor Clark & Lunn Investment Management Ltd. Has $5.19 Million Position in BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) - MarketBeat
Principal Financial Group Inc. Purchases 375,890 Shares of BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) - MarketBeat
Orladeyo now available to treat HAE patients in Ireland - Angioedema News Today
Hereditary Angioedema Therapeutics Market Report Outlines - openPR
Cystinosis Clinical Trials 2024: EMA, PDMA, FDA Approvals, - openPR
Counterweight Ventures LLC Increases Position in BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) - MarketBeat
Primary Hyperoxaluria Drug Market SWOT Analysis by Leading Key Players: Pfizer, Novartis, BioCryst - openPR
Short Interest in BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) Decreases By 7.5% - MarketBeat
BioCryst's ORLADEYO Becomes First Oral HAE Treatment Approved in Ireland - StockTitan
BioCryst Launches ORLADEYO® (berotralstat) in Ireland - GlobeNewswire
(BCRX) Pivots Trading Plans and Risk Controls - Stock Traders Daily
Avian influenza Treatment Market Growth Trends: Regional - openPR
BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) Shares Sold by GSA Capital Partners LLP - MarketBeat
BioCryst's SWOT analysis: stock outlook amid orladeyo success, pipeline shifts - Investing.com UK
BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) Given Consensus Rating of "Moderate Buy" by Analysts - MarketBeat
Vanguard Group Inc's Strategic Acquisition in BioCryst Pharmaceu - GuruFocus.com
HC Wainwright Has Optimistic Outlook of BCRX Q4 Earnings - MarketBeat
Clearside's Eye Treatment Platform Gains Momentum with Major Santen Partnership in China - StockTitan
Ionis Looks Ahead To Commercializing Its Own Products - Citeline
Objective long/short (BCRX) Report - Stock Traders Daily
BioCryst to Present at Upcoming Investor Conferences - GlobeNewswire
BioCryst (BCRX) to Present at Three Major Healthcare Investor Conferences | BCRX Stock News - StockTitan
BioCryst Pharmaceuticals (NASDAQ:BCRX) Posts Earnings Results, Hits Estimates - MarketBeat
BioCryst Pharmaceuticals' (BCRX) "Outperform" Rating Reiterated at Royal Bank of Canada - MarketBeat
Barclays Forecasts Strong Price Appreciation for BioCryst Pharmaceuticals (NASDAQ:BCRX) Stock - MarketBeat
BCRXBioCryst Pharmaceuticals Inc Latest Stock News & Market Updates - StockTitan
Biocryst Pharmaceuticals Inc Azioni (BCRX) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
2.88%
2.65%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):